Oridonin inhibits BxPC-3 cell growth through cell apoptosis

Acta Biochimica et Biophysica Sinica

Volumn 47, Issue 3, 2015, Pages 164-173

  Xu, Bin ^a   Shen, Wen ^b   Liu, Xing ^c   Zhang, Ting ^b   Ren, Jun ^b   Fan, Yongjun ^d   Xu, Jian ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^c JINGGANGSHAN UNIVERSITY   (China)

^d GRIFFITH UNIVERSITY   (Australia)

Author keywords

Apoptosis; BxPC 3 cells; Oridonin; Pancreatic cancer; Proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CDK1 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; H2AFX PROTEIN, HUMAN; HISTONE; KAURANE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ORIDONIN; PROTEIN P53; TP53 PROTEIN, HUMAN;

APOPTOSIS; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CELL SURVIVAL; CHINESE MEDICINE; DRUG EFFECTS; HUMAN; ISODON; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CASPASES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASES; DITERPENES, KAURANE; HISTONES; HUMANS; ISODON; MEDICINE, CHINESE TRADITIONAL; PANCREATIC NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84927936387     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmu134     Document Type: Article

References (44)

1. Dal Piaz F, Cotugno R, Lepore L, Vassallo A, Malafronte N, Lauro G, Bifulco G, et al. Chemical proteomics reveals HSP70 1A as a target for the anticancer diterpene oridonin in Jurkat cells. J Proteomics 2013, 82: 14-26.
2. de la Taille A, Hayek OR, Burchardt M, Burchardt T, Katz AE. Role of herbal compounds (PC-SPES) in hormone-refractory prostate cancer: Two case reports. J Altern Complement Med 2000, 6: 449-451.
3. Yance DR, Sagar SM. Targeting angiogenesis with integrative cancer therapies. Integr Cancer Ther 2006, 5: 9-29.
4. Hsiao W, Liu L. The role of traditional Chinese herbal medicines in cancer therapy - from TCM theory to mechanistic insights. Planta Med 2010, 76: 1118-1131.
5. Salminen A, Lehtonen M, Suuronen T, Kaarniranta K, Huuskonen J. Terpenoids: Natural inhibitors of NF-?B signaling with anti-inflammatory and anticancer potential. Cell Mol Life Sci 2008, 65: 2979-2999.
6. Xu Y, Xue Y,Wang Y, Feng D, Lin S, Xu L. Multiple-modulation effects of Oridonin on the production of proinflammatory cytokines and neurotrophic factors in LPS-activated microglia. Int Immunopharmacol. 2009, 9: 360-365.
7. Zhang Q, Yang S, Song A, Gong Y, Zhang T. Study on the antimutagenictty of oridonin. Carcinog Teratog Mutagen 2001, 13: 8-9.
8. Liu Z, Ouyang L, Peng H, Zhang WZ. Oridonin: Targeting programmed cell death pathways as an anti-tumour agent. Cell Prolif 2012, 45: 499-507.
9. Li D, Wu LJ, Tashiro SI, Onodera S, Ikejima T. Oridonin-induced A431 cell apoptosis partially through blockage of the Ras/Raf/ERK signal pathway. J Pharmacol Sci 2007, 103: 56-66.
10. Liu Y-Q, You S, Tashiro SI, Onodera S, Ikejima T. Activation of phosphoinositide 3-kinase, protein kinase C, and extracellular signal-regulated kinase is required for oridonin-enhanced phagocytosis of apoptotic bodies in human macrophage-like U937 cells. J Pharmacol Sci 2005, 98: 361-371.
11. Hsan KM, Chen CC, Shyur LF. Current research and development of chemotherapeutic agents for melanoma. Cancers (Basel) 2010, 2: 397-419.
12. Liffers ST, Tilkorn DJ, Stricker I, Junge CG, Al-Benna S, Voqt M, Verdoot B, et al. Salinomycin increases chemosensitivity to the effects of doxorubicin in soft tissue sarcomas. BMC Cancer 2013, 13: 490.
13. Zhang T, Tan Y, Zhao R, Liu Z. DNA damage induced by oridonin involves cell cycle arrest at G2/M phase in human MCF-7 cells. Contemp Oncol (Pozn) 2013, 17: 3844.
14. Sun KW, Ma YY, Guan TP, Xia YJ, Shao CM, Chen LG, Ren YJ, et al. Oridonin induces apoptosis in gastric cancer through Apaf-1, cytochrome c and caspase-3 signaling pathway. World J Gastroenterol 2012, 18: 7166-7174.
15. Yang H, Dou QP. Targeting apoptosis pathway with natural terpenoids: Implications for treatment of breast and prostate cancer. Curr Drug Targets 2010, 11: 733-744.
16. Wong AM, Zhang Y, Kesler K, Deng M, Burhenn L,Wang D, Moro A, et al. Genomic and in vivo evidence of synergy of a herbal extract compared to its most active ingredient: Rabdosia rubescens vs. oridonin. Exp Ther Med 2010, 1: 1013-1017.
17. Zhou GB, Kang H,Wang L, Gao L, Liu P, Xie J, Zhang FX, et al. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t (8; 21) leukemia in vitro and in vivo. Blood 2007, 109: 3441-3450.
18. Qi X, Zhang D, Xu X, Feng F, Ren G, Chu Q, Zhang Q, et al. Oridonin nanosuspension was more effective than free oridonin on G2/M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line. Int J Nanomedicine 2011, 7: 1793-1804.
19. Gao FH, Hu XH, LiW, Liu H, Zhang YJ, Guo ZY, Xu MH, et al. Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer 2010, 10: 610.
20. Li X,Wang J, Ye Z, Li JC. Oridonin up-regulates expression of P21 and induces autophagy and apoptosis in human prostate cancer cells. Int J Biol Sci 2012, 8: 901-912.
21. Wang H, Ye Y, Chu JH, Zhu GY, Li YW, Fong DW, Yu ZL. Oridonin induces G2/Mcell cycle arrest and apoptosis through MAPK and p53 signaling pathways in HepG2 cells. Oncol Rep 2010, 24: 647-651.
22. Hu HZ, Yang YB, Xu XD, Shen HW, Shu YM, Ren Z, Li XM, et al. Oridonin induces apoptosis via PI3K/Akt pathway in cervical carcinoma HeLa cell line. Acta Pharmacol Sin 2007, 28: 1819-1826.
23. Liu Y, You S, Tashiro S, Onodera S, Ikejima T. Oridonin induced U937 cell apoptosis through ERK pathway. Zhongguo Zhong Yao Za Zhi 2005, 30: 1856-1859.
24. Biswas R, Chung PS, Moon JH, Lee SH, Ahn JC. Carboplatin synergistically triggers the efficacy of photodynamic therapy via caspase 3-, 8-, and 12-dependent pathways in human anaplastic thyroid cancer cells. Lasers Med Sci 2014, 29: 995-1007.
25. Cui Q, Yu JH, Wu JN, Tashiro S, Onodera S, Minami M, Ikejima T. P53- mediated cell cycle arrest and apoptosis through a caspase-3-independent, but caspase-9-dependent pathway in oridonin-treated MCF-7 human breast cancer cells. Acta Pharmacol Sin 2007, 28: 1057-1066.
26. Neoptolemos J, Cunningham D, Friess H, Bassi C, Stocken DD, Tait DM, Dunn JA, et al. Adjuvant therapy in pancreatic cancer: Historical and current perspectives. Ann Oncol 2003, 14: 675-692.
27. Yokoyama Y, Nimura Y, Nagino M. Advances in the treatment of pancreatic cancer: Limitations of surgery and evaluation of new therapeutic strategies. Surg Today 2009, 39: 466-475.
28. Chang HW, Kim SY, Yi SL, Son SH, Song DY, Moon SY, Sim JH, et al. Expression of Ku80 correlates with sensitivities to radiation in cancer cell lines of the head and neck. Oral Oncol 2006, 42: 979-986.
29. Lowndes NF, Toh GW. DNA repair: The importance of phosphorylating histone H2AX. Curr Biol 2005, 15: 99-102.
30. Pinto DM, Flaus A. Structure and function of histone H2AX. Subcell Biochem 2010, 50: 55-78.
31. Ye X, Franco AA, Santos H, Nelson DM, Kaufman PD, Adams PD. Defective S phase chromatin assembly causes DNA damage, activation of the S phase checkpoint, and S phase arrest. Mol Cell 2003, 11: 341-351.
32. Castedo M, Perfettini JL, Roumier T, Kroemer G. Cyclin-dependent kinase-1: Linking apoptosis to cell cycle and mitotic catoastrophe. Cell Death Differ 2002, 9: 1287-1293.
33. Yun J, Chae HD, Choy HE, Chung J, Yoo HS, Han MH, Shin DY. p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. J Biol Chem 1999, 274: 29677-29682.
34. Sharma MR, Tuszynski GP, Sharma MC. Angiostatin-induced inhibition of endothelial cell proliferation/apoptosis is associated with the down-regulation of cell cycle regulatory protein cdk5. J Cell Biochem 2004, 91: 398-409.
35. Zhou M, Gu L, Li F, Zhu Y, Woods WG, Findley HW. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther 2002, 303: 124-131.
36. Fan TJ, Han LH, Cong RS, Liang J. Caspase family proteases and apoptosis. Acta Biochim Biophys Sin 2005, 37: 719-727.
37. Nicholson DW. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 1999, 6: 1028-1042.
38. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, et al. Identification and inhibition of the ICE/ CED-3 protease necessary for mammalian apoptosis. Nature 1995, 376: 37-43.
39. Cohen GM. Caspases: The executioners of apoptosis. Biochem J 1997, 326: 1-16.
40. Freire R, d'Adda Di Fagagna F, Wu L, Pedrazzi G, Stagljar I, Hickson ID, Jackson SP. Cleavage of the Bloom's syndrome gene product during apoptosis by caspase-3 results in an impaired interaction with topoisomerase IIIa. Nucleic Acids Res 2001, 29: 3172-3180.
41. Germain M, Affar EB, D'Amours D, Dixit VM, Salvesen GS, Poirier GG. Cleavage of automodified poly (ADP-ribose) polymerase during apoptosis Evidence for involvement of caspase-7. J Biol Chem 1999, 274: 28379-28384.
42. Herceg Z, Wang ZQ. Functions of poly (ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat Res 2001, 477: 97-110.
43. Yu SW, Andrabi SA, Wang H, Kim NS, Poirier GG, Dawson TM, Dawson VL. Apoptosis-inducing factor mediates poly (ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci USA 2006, 103: 18314-18319.
44. Wang Y, Kim NS, Haince JF, Kang HC, David KK, Andrabi SA, Poirier GG, et al. Poly (ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos) . Sci Signal 2011, 4: Ra20.